局限性与转移性前列腺癌中TP53、PTEN和RB1抑癌基因的复合基因组改变
该研究对285例前列腺癌标本(局限性和转移性去势敏感及去势抵抗)行靶向测序,发现抑癌基因变异随疾病进展增加(L-CSPC 39%,M1-CSPC 63%,M1-CRPC 92%)。TSG改变的L-CSPC患者无事件生存期更短(中位2.6年,HR 1.95,95%CI 1.22-3.13),且累积基因命中数增加复发风险(2-3个基因 vs 0个:HR 2.70,95%CI 1.43-5.08,p=0.004)。
要点
- 抑癌基因变异率随疾病进展升高:L-CSPC 39%,M1-CSPC 63%,M1-CRPC 92%。
- TSG改变的局限期患者无事件生存期缩短(中位2.6年,HR 1.95)。
- 累积基因命中增加复发风险,2-3个基因HR 2.70(95%CI 1.43-5.08)。
核心结论
- 有害TSG变异与CSPC复发(局限期)和死亡(转移期)风险增加相关。
- 复合基因命中在早期和晚期疾病中均见更差结局,部分反映整体基因组不稳定。
研究设计与样本
- 采用大规模平行靶向测序对285例前列腺癌标本(包括局限性和转移性去势敏感及去势抵抗)进行分析。
- TSG改变定义为TP53、PTEN和RB1中一个或多个基因的拷贝数丢失或有害突变。
主要发现
- TSG变异率随疾病进展增加:L-CSPC 39%,M1-CSPC 63%,M1-CRPC 92%。
- TSG改变的L-CSPC患者无事件生存期更短(中位2.6年,HR 1.95,95%CI 1.22-3.13)。
- TSG改变的L-CSPC患者至CRPC时间更短(中位9.5个月,HR 3.36,95%CI 1.01-11.16)。
- 累积基因命中增加复发风险:1个基因HR 1.69(95%CI 0.99-2.87),2-3个基因HR 2.70(95%CI 1.43-5.08),两者 vs 0个基因p=0.004。
- 转移队列中随TSG命中数增加有总生存期更差的证据;M1-CRPC队列仅4例(8%)为TSG阴性,其中1例于5.2年后死亡。
临床怎么用
- 复合TSG突变提示侵袭性特征,可能帮助识别可从强化治疗中获益的患者。
局限性
- 调整突变和拷贝数负荷的多变量分析未显示累积基因命中与更差结局的显著独立关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may drive more aggressive disease. OBJECTIVE: To determine clinical outcomes of single and compound TSG alterations across the spectrum of prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Massively parallel targeted sequencing using castration-sensitive prostate cancer (CSPC; localized [L] and metastatic [M1]) and castration-resistant prostate cancer (CRPC) specimens (n=285). TSG altered (TSG-alt) was any copy number loss or deleterious mutation of one or more TSGs (TP53, PTEN, and RB1). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: For L-CSPC, event-free survival (EFS) and time to CRPC were estimated. For M1-CSPC and M1-CRPC, overall survival (OS) was estimated. Cox regression models assessed the association between cumulative TSG hits (zero hits vs one hit vs two to three hits) and outcomes with multivariable analyses adjusted for clinicopathological factors. RESULTS AND LIMITATIONS: TSG variants increased with advanced disease (L-CSPC: 39%; M1-CSPC: 63%, M1-CRPC: 92%). TSG-alt L-CSPC had shorter EFS (median 2.6yr, hazard ratio [HR] 1.95, 95% confidence interval [CI] 1.22-3.13) and time to CRPC (median 9.5mo, HR 3.36, 95% CI 1.01-11.16). Cumulative gene hits led to an incremental risk of relapse (EFS: one gene, HR 1.69, 95% CI 0.99-2.87; two to three genes, HR 2.70, 95% CI 1.43-5.08; both versus zero genes, p=0.004). There was evidence of inferior OS with increasing TSG hits in the metastatic cohorts. Only four (8%) patients in the M1-CRPC cohort were TSG-neg, one of whom died after 5.2yr. Multivariable analyses adjusting for mutational and copy number burden did not demonstrate a significant independent association of increasing gene hits and poorer outcomes. CONCLUSIONS: Deleterious TSG variants are associated with an increased risk of relapse (L) and death (M1) in CSPC. Poorer outcomes are seen with compound gene hits in both early and advanced disease, and this may in part reflect increasing global genomic instability. PATIENT SUMMARY: Men with prostate tumors with compound tumor suppressor gene mutations have poorer outcomes. These findings help identify patients with aggressive features who may benefit from intensified treatment.
引用
- Hamid AA, Gray KP, Shaw G, et al. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2018. PMID: 30553611. doi:10.1016/j.eururo.2018.11.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。